|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/06/24 Adaptimmune Therapeutics plc 10-K 12/31/23 131:16M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 3.61M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 125K
3: EX-19.1 Report Furnished to Security Holders HTML 110K
4: EX-21.1 Subsidiaries List HTML 37K
5: EX-23.1 Consent of Expert or Counsel HTML 35K
10: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 50K
Awarded Compensation
6: EX-31.1 Certification -- §302 - SOA'02 HTML 41K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 41K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 37K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 37K
16: R1 Document and Entity Information HTML 102K
17: R2 Condensed Consolidated Balance Sheets HTML 132K
18: R3 Condensed Consolidated Balance Sheets HTML 58K
(Parenthetical)
19: R4 Condensed Consolidated Statements of Operations HTML 102K
20: R5 Condensed Consolidated Statements of Comprehensive HTML 65K
Loss
21: R6 Condensed Consolidated Statements of Comprehensive HTML 47K
Income/Loss (Parenthetical)
22: R7 Condensed Consolidated Statements of Change in HTML 90K
Equity
23: R8 Condensed Consolidated Statements of Cash Flows HTML 121K
24: R9 General HTML 40K
25: R10 Summary of Significant Accounting Policies HTML 370K
26: R11 Revenue HTML 88K
27: R12 Financial instruments HTML 111K
28: R13 Other current assets HTML 53K
29: R14 Property, plant and equipment, net HTML 58K
30: R15 Intangible assets, net HTML 50K
31: R16 Operating Leases HTML 88K
32: R17 Accrued expenses and other current liabilities HTML 57K
33: R18 Contingencies and commitments HTML 51K
34: R19 Stockholders' equity HTML 48K
35: R20 Share-based compensation HTML 265K
36: R21 Income taxes HTML 185K
37: R22 Geographic information HTML 53K
38: R23 Restructuring HTML 113K
39: R24 Business combinations HTML 97K
40: R25 Subsequent events HTML 39K
41: R26 Summary of Significant Accounting Policies HTML 429K
(Policies)
42: R27 Summary of Significant Accounting Policies HTML 321K
(Tables)
43: R28 Revenue (Tables) HTML 54K
44: R29 Financial instruments (Tables) HTML 106K
45: R30 Other current assets (Tables) HTML 52K
46: R31 Property, plant and equipment, net (Tables) HTML 56K
47: R32 Intangible assets, net (Tables) HTML 50K
48: R33 Operating Leases (Tables) HTML 88K
49: R34 Accrued expenses and other current liabilities HTML 53K
(Tables)
50: R35 Share-based compensation (Tables) HTML 254K
51: R36 Income taxes (Tables) HTML 185K
52: R37 Geographic information (Tables) HTML 48K
53: R38 Restructuring (Tables) HTML 112K
54: R39 Business combinations (Tables) HTML 91K
55: R40 General (Details) HTML 39K
56: R41 Summary of Significant Accounting Policies - HTML 38K
Foreign currency (Details)
57: R42 Summary of Significant Accounting Policies - HTML 74K
Changes in Accumulated other comprehensive (Loss)
Income (Details)
58: R43 Summary of Significant Accounting Policies - HTML 39K
Reclassification out of Other comprehensive (Loss)
Income (Details)
59: R44 Summary of Significant Accounting Policies - Cash, HTML 45K
cash equivalents and restricted cash (Details)
60: R45 Summary of Significant Accounting Policies - HTML 116K
Available-for-sale debt securities (Details)
61: R46 Summary of Significant Accounting Policies - HTML 38K
Accounts receivable (Details)
62: R47 Summary of Significant Accounting Policies - HTML 45K
Property, plant and equipment (Details)
63: R48 Summary of Significant Accounting Policies - HTML 38K
Intangibles (Details)
64: R49 Summary of Significant Accounting Policies - HTML 43K
Leases (Details)
65: R50 Summary of Significant Accounting Policies - HTML 38K
Segment Reporting (Details)
66: R51 Summary of Significant Accounting Policies - HTML 42K
Research and Development Expenditure (Details)
67: R52 Summary of Significant Accounting Policies - HTML 37K
Retirement Benefits (Details)
68: R53 Summary of Significant Accounting Policies - HTML 37K
Interest income (Details)
69: R54 Summary of Significant Accounting Policies - Loss HTML 64K
per share (Details)
70: R55 Summary of Significant Accounting Policies - HTML 39K
Antidilutive Securities (Details)
71: R56 Summary of Significant Accounting Policies - HTML 42K
Options (Details)
72: R57 Revenue - Revenue from contracts with customers HTML 70K
(Details)
73: R58 Revenue - Collaboration Agreement - The Genentech HTML 108K
Collaboration and License Agreement (Details)
74: R59 Revenue - Collaboration Agreement - The Astellas HTML 46K
Collaboration Agreement (Details)
75: R60 Revenue - Collaboration Agreement - The GSK HTML 45K
Collaboration and License Agreement (Details)
76: R61 Revenue - Collaboration Agreement - The GSK HTML 61K
Termination and Transfer Agreement (Details)
77: R62 Financial instruments - Fair value of assets and HTML 57K
liabilities (Details)
78: R63 Financial instruments - Cash Equivalents and HTML 44K
Short-term Deposits (Details)
79: R64 Financial instruments - Collaboration and License HTML 42K
Agreement (Details)
80: R65 Financial instruments - Foreign Exchange Risk HTML 37K
(Details)
81: R66 Other current assets (Details) HTML 50K
82: R67 Property, plant and equipment, net - Schedule of HTML 54K
Property and Equipment (Details)
83: R68 Property, plant and equipment, net - Depreciation HTML 38K
Expense (Details)
84: R69 Intangible assets, net - Tabular Disclosure HTML 46K
(Details)
85: R70 Intangible assets, net - Amortization Expense HTML 38K
(Details)
86: R71 Intangible assets, net - Aggregate Amortization HTML 47K
Expense (Details)
87: R72 Operating Leases (Details) HTML 49K
88: R73 Operating Leases - Maturities (Details) HTML 54K
89: R74 Accrued expenses and other current liabilities HTML 48K
(Details)
90: R75 Contingencies and commitments - Capital HTML 43K
Commitments (Details)
91: R76 Contingencies and commitments - Clinical Trials HTML 48K
and Contract Manufacturing Commitments (Details)
92: R77 Contingencies and commitments - MD Anderson HTML 45K
Strategic Alliance (Details)
93: R78 Contingencies and commitments - Universal Cells HTML 50K
Research, Collaboration and License Agreement and
Co-development and Co-commercialization agreement
(Details)
94: R79 Contingencies and commitments - Noile-Immune HTML 43K
Collaboration Agreement (Details)
95: R80 Contingencies and commitments - Alpine HTML 45K
Collaboration Agreement (Details)
96: R81 Contingencies and commitments - ThermoFisher HTML 44K
License Agreement (Details)
97: R82 Stockholders' equity - Ordinary Shares (Details) HTML 43K
98: R83 Stockholders equity - Offerings (Details) HTML 63K
99: R84 Share-based compensation - Option Plans (Details) HTML 136K
100: R85 Share-based compensation - Share-based HTML 42K
Compensation Expense (Details)
101: R86 Share based compensation - Unrecognized HTML 40K
Compensation Cost (Details)
102: R87 Share-based compensation - Options (Details) HTML 46K
103: R88 Share based compensation - Option Activity HTML 102K
(Details)
104: R89 Share based compensation - Options Exercised HTML 46K
(Details)
105: R90 Share based compensation - Stock Options HTML 90K
Outstanding (Details)
106: R91 Share-based compensation - Fair Value Assumptions HTML 51K
(Details)
107: R92 Income taxes - Loss before Income Taxes (Details) HTML 45K
108: R93 Income taxes - Components of Income Tax Expense HTML 52K
(Benefit) (Details)
109: R94 Income taxes - Reconciliation of Deferred Tax HTML 69K
Assets and Liabilities (Details)
110: R95 Income taxes - Change in Valuation Allowance HTML 47K
(Details)
111: R96 Income taxes - Reconciliation of Effective Tax HTML 63K
Rate (Details)
112: R97 Income taxes - Change in Tax Rate (Details) HTML 67K
113: R98 Income taxes - Unrecognized Tax Benefits (Details) HTML 37K
114: R99 Geographic information - Operations by Geographic HTML 41K
Area - Long-lived Assets (Details)
115: R100 Geographic information - Major Customers (Details) HTML 46K
116: R101 Restructuring (Details) HTML 50K
117: R102 Restructuring - Movements in Provision (Details) HTML 58K
118: R103 Restructuring - TCR post-acquisition senior HTML 49K
leadership severance (Details)
119: R104 Restructuring - TCR post-acquisition senior HTML 48K
leadership severance - Change in Liability
(Details)
120: R105 Business combinations (Details) HTML 99K
121: R106 Business combinations - Gain on bargain purchase HTML 53K
(Details)
122: R107 Business combinations - Proforma Information HTML 57K
(Details)
123: R108 Business combinations - Acquisition-related costs HTML 45K
(Details)
124: R109 Subsequent Events - 2022 Sales Agreement (Details) HTML 48K
125: R110 Pay vs Performance Disclosure HTML 48K
126: R111 Insider Trading Arrangements HTML 41K
128: XML IDEA XML File -- Filing Summary XML 244K
131: XML XBRL Instance -- adap-20231231x10k_htm XML 4.06M
127: EXCEL IDEA Workbook of Financial Report Info XLSX 231K
12: EX-101.CAL XBRL Calculations -- adap-20231231_cal XML 229K
13: EX-101.DEF XBRL Definitions -- adap-20231231_def XML 1.00M
14: EX-101.LAB XBRL Labels -- adap-20231231_lab XML 1.86M
15: EX-101.PRE XBRL Presentations -- adap-20231231_pre XML 1.46M
11: EX-101.SCH XBRL Schema -- adap-20231231 XSD 302K
129: JSON XBRL Instance as JSON Data -- MetaLinks 657± 1.03M
130: ZIP XBRL Zipped Folder -- 0001558370-24-002537-xbrl Zip 1.23M
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference, in the registration statements No. 333-264208 on Form S-3 and Nos. 333-275813, 333-233558 and 333-203929 on Form S-8, of our report dated March 6, 2024, with respect to the consolidated financial statements of Adaptimmune Therapeutics plc.
/s/ KPMG LLP
Reading, United Kingdom
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/6/24 | 8-K | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||